GeneDx Price Fair Value from 2010 to 2024

WGS Stock   79.43  1.09  1.35%   
GeneDx Holdings Price Fair Value yearly trend continues to be comparatively stable with very little volatility. Price Fair Value is likely to outpace its year average in 2024. From the period from 2010 to 2024, GeneDx Holdings Price Fair Value quarterly data regression had mean square error of  0.09 and mean deviation of  0.24. View All Fundamentals
 
Price Fair Value  
First Reported
2010-12-31
Previous Quarter
0.29321485
Current Value
0.52
Quarterly Volatility
0.34194115
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check GeneDx Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeneDx Holdings' main balance sheet or income statement drivers, such as Net Interest Income of 1.2 M, Interest Income of 3.1 M or Depreciation And Amortization of 30.9 M, as well as many indicators such as Price To Sales Ratio of 0.31, Dividend Yield of 0.0 or PTB Ratio of 0.52. GeneDx financial statements analysis is a perfect complement when working with GeneDx Holdings Valuation or Volatility modules.
  
Check out the analysis of GeneDx Holdings Correlation against competitors.

Latest GeneDx Holdings' Price Fair Value Growth Pattern

Below is the plot of the Price Fair Value of GeneDx Holdings Corp over the last few years. It is GeneDx Holdings' Price Fair Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeneDx Holdings' overall financial position and show how it may be relating to other accounts over time.
Price Fair Value10 Years Trend
Slightly volatile
   Price Fair Value   
       Timeline  

GeneDx Price Fair Value Regression Statistics

Arithmetic Mean0.16
Coefficient Of Variation213.29
Mean Deviation0.24
Median(0.0002)
Standard Deviation0.34
Sample Variance0.12
Range1.2422
R-Value0.57
Mean Square Error0.09
R-Squared0.32
Significance0.03
Slope0.04
Total Sum of Squares1.64

GeneDx Price Fair Value History

2024 0.52
2023 0.29
2022 0.35
2021 1.24

About GeneDx Holdings Financial Statements

GeneDx Holdings shareholders use historical fundamental indicators, such as Price Fair Value, to determine how well the company is positioned to perform in the future. Although GeneDx Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in GeneDx Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on GeneDx Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Price Fair Value 0.29  0.52 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.